OptimizeRx Stock Forecast, Price & News

OptimizeRx (NASDAQ:OPRX) Frequently Asked Questions

Is OptimizeRx a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx or view top-rated stocks.

How has OptimizeRx's stock price been impacted by COVID-19 (Coronavirus)?

OptimizeRx's stock was trading at $7.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, OPRX stock has increased by 447.3% and is now trading at $41.10.
View which stocks have been most impacted by COVID-19.

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for OptimizeRx.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) announced its quarterly earnings data on Tuesday, November, 9th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The company earned $16.13 million during the quarter, compared to the consensus estimate of $14.82 million. OptimizeRx had a trailing twelve-month return on equity of 2.03% and a net margin of 4.16%. During the same quarter last year, the company earned ($0.01) earnings per share.
View OptimizeRx's earnings history.

What price target have analysts set for OPRX?

5 Wall Street analysts have issued 1-year price targets for OptimizeRx's shares. Their forecasts range from $54.00 to $112.00. On average, they expect OptimizeRx's stock price to reach $92.00 in the next year. This suggests a possible upside of 123.8% from the stock's current price.
View analysts' price targets for OptimizeRx or view top-rated stocks among Wall Street analysts.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:

• Will Febbo, Chief Executive Officer & Director
• Edward Stelmakh, Chief Operations & Financial Officer
• Todd Inman, Chief Technology Officer
• Marion K. Odence-Ford, Chief Compliance Officer & General Counsel
• Angelo Campano, Senior Vice President & Principal-Agency Channels

Who are some of OptimizeRx's key competitors?

Some companies that are related to OptimizeRx include Flywire (FLYW), Fiverr International (FVRR), MultiPlan (MPLN), First Advantage (FA), Paysafe (PSFE), TechTarget (TTGT), OLO (OLO), Zhihu (ZH), ACV Auctions (ACVA), Advantage Solutions (ADV), Xometry (XMTR), CBIZ (CBZ), EVO Payments (EVOP), GreenSky (GSKY) and Payoneer Global (PAYO).
View all of OPRX's competitors.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Russell Investments Group Ltd. (0.34%), New York State Teachers Retirement System (0.10%), State of Alaska Department of Revenue (0.07%), Precision Wealth Strategies LLC (0.06%), Louisiana State Employees Retirement System (0.05%) and Cutler Group LP (0.00%). Company insiders that own OptimizeRx stock include Douglas P Baker, Douglas P Baker, Ellen O'connor Vos, Gregory D Wasson, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends for OptimizeRx.

Which major investors are selling OptimizeRx stock?

OPRX stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. Company insiders that have sold OptimizeRx company stock in the last year include Douglas P Baker, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, and William J Febbo.
View insider buying and selling activity for OptimizeRx or view top insider-selling stocks.

Which major investors are buying OptimizeRx stock?

OPRX stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, State of Alaska Department of Revenue, Louisiana State Employees Retirement System, Precision Wealth Strategies LLC, and Cutler Group LP. Company insiders that have bought OptimizeRx stock in the last two years include Ellen O'connor Vos, and Gregory D Wasson.
View insider buying and selling activity for OptimizeRx or or view top insider-buying stocks.

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $41.10.

How much money does OptimizeRx make?

OptimizeRx has a market capitalization of $730.35 million and generates $43.31 million in revenue each year. The company earns $-2.21 million in net income (profit) each year or $0.14 on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 2,018 workers across the globe.

What is OptimizeRx's official website?

The official website for OptimizeRx is www.optimizerx.com.

Where are OptimizeRx's headquarters?

OptimizeRx is headquartered at 400 WATER STREET SUITE 200, ROCHESTER MI, 48307.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The company can be reached via phone at (248) 651-6568, via email at [email protected], or via fax at 248-453-5529.